Wegovy Treatment Length: How Long Do You Actually Take It?

You've reached month three and you're wondering whether this is forever

It's a question our prescribers hear regularly. By the time the dose titration settles and appetite genuinely starts to change, many people begin weighing up the longer picture: months? Years? Indefinitely? The uncertainty is understandable, and the short answer is that Wegovy is not designed as a permanent prescription by default, but it is also not a short course like antibiotics.

The NICE technology appraisal for semaglutide (TA875) sets a clear outer limit: semaglutide for weight management should be used for a maximum of two years, and only within a specialist weight management service that includes multidisciplinary support. That framing matters. The two years is not a guaranteed entitlement, it is the ceiling under which a prescriber monitors progress and decides, at each review, whether continuing makes sense.

There is also a checkpoint built into the guidance. If someone has not lost at least 5% of their starting body weight after six months at the maintenance dose, the clinical recommendation is to reconsider continuing. That figure comes directly from the trial data and is reflected in the NICE criteria. It exists because semaglutide works well for most people who respond to it, and for those who do not, extending treatment carries cost and side-effect burden without meaningful benefit.

None of this means treatment will automatically stop at two years. It means the two-year mark triggers a structured review, not a cliff edge.

What happens to weight when Wegovy stops, and why that shapes the length question

One misconception worth setting aside gently: the idea that you take Wegovy, lose the weight, stop, and the result simply stays. The clinical evidence does not support that picture. Appetite-regulating mechanisms that semaglutide influences tend to reassert themselves after stopping, and weight regain is common.

The STEP 1 trial, published in the New England Journal of Medicine, followed participants after the treatment period and found substantial weight regain in the year after semaglutide was stopped. This is not a failure of the medicine, it reflects the biology of obesity as a chronic condition rather than a problem that is solved and filed away.

What that means practically is that the question of treatment length is rarely just about hitting a number on the scales. It is about what support exists during treatment, what lifestyle changes have taken root, and what the plan looks like if and when the medicine stops. Those conversations belong with your prescribing team. For an overview of what Wegovy treatment involves more broadly, including how the dose schedule works and what to expect month by month, that page covers the full picture.

Private treatment, NHS treatment, and who sets the clock

On the NHS, the two-year NICE limit is applied within specialist services, and access to those services currently involves waiting lists that are, in many areas, significant. The two-year clock also runs from the point treatment starts, not from when it was approved or prescribed. For people in the region who are exploring Wegovy treatment in Essex through a regulated private service, prescribing decisions are made individually at each review, with the NICE two-year recommendation remaining the clinical reference point.

At nume, there are no subscriptions and no automatic renewals. Every repeat order goes back to a GPhC-registered prescriber for a fresh clinical review (weight progress, tolerability, any changes to health) before anything is dispensed. That means the length of treatment is genuinely determined by clinical progress rather than by a standing order. For those considering how semaglutide treatment fits their specific situation, or exploring how Wegovy treatment works through a private service, our prescribers can talk through the timeline at consultation.

It is also worth knowing that what you eat during treatment can influence both tolerability and results. Protein intake, fibre, and managing the GI side effects that tend to peak in early titration all play a role in how smoothly treatment runs, and that has a bearing on whether you can sustain the full recommended period. Our guide to eating on Wegovy covers the practical detail, including what to prioritise if nausea is affecting your appetite.

If you have questions about where you would fit within current eligibility criteria or what a clinical review through our service involves, the best starting point is a free consultation with our prescribers. There is no obligation, and the assessment is thorough. Start your free consultation here.